<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="36927">[14C]</z:chebi>-<z:chebi fb="19" ids="28790">Serotonin</z:chebi> release assay (<z:chebi fb="32" ids="36927">14C</z:chebi>-SRA) from platelets is considered to be the most sensitive test for laboratory confirmation of <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> (HIT) </plain></SENT>
<SENT sid="1" pm="."><plain>This study compared <z:chebi fb="32" ids="36927">14C</z:chebi>-SRA with an enzyme immunoassay (EIA) to determine the release of <z:chebi fb="19" ids="28790">serotonin</z:chebi> from platelets in the presence of <z:chebi fb="5" ids="28304">heparin</z:chebi> and serum from HIT patients </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:mpath ids='MPATH_458'>normal</z:mpath> range (median, 2.5 and 97.5 percentiles) of <z:chebi fb="19" ids="28790">serotonin</z:chebi> release from platelets in healthy subjects (n = 149) is 38 ng/ml (19 and 62) measured by EIA-SRA </plain></SENT>
<SENT sid="3" pm="."><plain>Serum from HIT patients (n = 42) released 2548 ng/ml (244 and 7987) <z:chebi fb="19" ids="28790">serotonin</z:chebi> in the presence of 0.1 IU/ml <z:chebi fb="5" ids="28304">heparin</z:chebi> and 29 ng/ml (13 and 76) in the presence of 100 IU/ml <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>One hundred per cent and 15% of HIT samples exhibited an elevated <z:chebi fb="19" ids="28790">serotonin</z:chebi> release from platelets in the presence of 0.1 IU/ml low molecular weight (LMW) <z:chebi fb="5" ids="28304">heparin</z:chebi>, 2100 ng/ml (869 and 5968), or danaparoid, 272 ng/ml (143 and 403), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The sensitivity and specificity of the EIA-SRA was 100% and 97.4% and of the <z:chebi fb="32" ids="36927">14C</z:chebi>-SRA 100% and 92.9% in HIT patients </plain></SENT>
<SENT sid="6" pm="."><plain>No false-positive results were found in patients receiving <z:chebi fb="5" ids="28304">heparin</z:chebi> (n = 28), in patients with elevated levels of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> (n = 5), in patients with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (n = 10) or in non-HIT patients (n = 78) with both assays </plain></SENT>
<SENT sid="7" pm="."><plain>The EIA technique to quantify <z:chebi fb="19" ids="28790">serotonin</z:chebi> release from platelets provides a reliable non-radioactive method to diagnose <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> and to assess in vitro crossreactivity of low molecular weight <z:chebi fb="0" ids="24505">heparins</z:chebi> and heparinoid </plain></SENT>
</text></document>